Abstract Number: 042 • 2020 Pediatric Rheumatology Symposium
Safety Analysis of Infliximab-dyyb as Compared to Infliximab in Pediatric Rheumatic Conditions
Background/Purpose: Infliximab is an effective treatment for many pediatric rheumatic conditions, but high medication cost creates a barrier to patient access. Biosimilar drugs are proven…Abstract Number: 061 • 2020 Pediatric Rheumatology Symposium
Perspectives of Radiologist Physicians in the Imaging of Chronic Nonbacterial Osteomyelitis
Background/Purpose: Radiological imaging is integral to the diagnosis of chronic nonbacterial osteomyelitis (CNO) and has been included as a central component in suggested diagnostic criteria…Abstract Number: 066 • 2020 Pediatric Rheumatology Symposium
Baseline Kidney Biopsy in Lupus Patients Without Renal Manifestations. Underappreciated or Overrated?
Background/Purpose: Lupus nephritis (LN) is seen in 20–75% of patients with pediatric Systemic Lupus Erythematosus (SLE). LN may present with abnormal urinary findings and/or renal…Abstract Number: 093 • 2020 Pediatric Rheumatology Symposium
Treatment of Systemic Juvenile Idiopathic Arthritis in the CARRA Registry
Background/Purpose: The treatment of systemic juvenile idiopathic arthritis (SJIA) has changed dramatically over the past decade, associated with overall improvement in functional outcomes. There may…Abstract Number: 135 • 2020 Pediatric Rheumatology Symposium
Use of Intravenous Pamidronate in Pediatric Leukemia Patients with Osteonecrosis Results in Reduced Pain and May Halt Osteonecrosis Progression
Background/Purpose: Osteonecrosis has emerged as debilitating complication of acute pediatric lymphoblastic leukemia (pALL), with severe pain and poor functional outcome. Patients with ON of weight…Abstract Number: 176 • 2020 Pediatric Rheumatology Symposium
Implementation of an Abbreviated Neuropsychology Screening Protocol for Patients Diagnosed with Childhood-onset Systemic Lupus Erythematosus
Background/Purpose: Research has established that a large percentage of individuals diagnosed with childhood-onset systemic lupus erythematosus (cSLE) report cognitive dysfunction. Disease factors that can impact…Abstract Number: 192 • 2020 Pediatric Rheumatology Symposium
Single Center Consensus of Prophylactic Treatment in Immunocompromised Children with Rheumatic Disease
Background/Purpose: Many children with rheumatic diseases require immunosuppressive treatments, however these medications put them at risk for contracting opportunistic infections leading to severe morbidity and…Abstract Number: 1729 • 2019 ACR/ARP Annual Meeting
Infections and Mortality in 230 Childhood Lupus Patients: A Single Center Experience from North India
Background/Purpose: Children with systemic lupus erythematosus(cSLE) have more severe disease as compared to adults. Additionally, Asians in their geographic area have high burden of infections…Abstract Number: 1754 • 2019 ACR/ARP Annual Meeting
Comorbidities and Treatments in United States Youth with Chronic Musculoskeletal Pain
Background/Purpose: Chronic musculoskeletal (MSK) pain has been associated with chronic illnesses, including mental disorders, and with high rates of pain medication use, often in referral…Abstract Number: 2296 • 2017 ACR/ARHP Annual Meeting
Infliximab Use in JIA and Uveitis: Does Methotrexate Help or Hinder?
Background/Purpose: Infliximab (IFX) effectiveness is impacted in part by immunogenicity and the development of drug neutralizing anti-drug antibodies, thus methotrexate is commonly co-administered to minimize…Abstract Number: 2997 • 2017 ACR/ARHP Annual Meeting
Patient and Family Reported Psychosocial Areas of Concern within Pediatric Rheumatology: Quality Improvement Data and Implications for Practice
Background/Purpose: Psychosocial factors greatly impact the subjective disease experience and outcomes of children with rheumatic conditions. Attention to the psychosocial aspects of patients’ needs is…Abstract Number: 42 • 2017 Pediatric Rheumatology Symposium
Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than Two Years of Age With Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Tocilizumab (TCZ) is approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) based on clinical trials in patients ≥2 years of age. This…Abstract Number: 100 • 2017 Pediatric Rheumatology Symposium
Improvement of Salivary Gland Ultrasound Findings in Juvenile Sjögren’s Syndrome after Systemic Corticosteroid Treatment
Background/Purpose: Juvenile Sjögren’sSyndrome (jSS) is a rare systemic autoimmune disease affecting predominantly salivary glands (SG) in children who do not meet criteria for SLE or MCTD. Currently, no specific criteria for…Abstract Number: 1391 • 2016 ACR/ARHP Annual Meeting
Novel Electronic Health Record-Based Method Confirms Increased Renal Disease Burden in Pediatric-Onset Vs. Adult-Onset Patients with Systemic Lupus Erythematosus
Background/Purpose: Children with Systemic Lupus Erythematosus (SLE) are often understudied compared with adults. Using the electronic health record (EHR) can increase sample size and the…Abstract Number: 1399 • 2016 ACR/ARHP Annual Meeting
Transitioning Lupus Patients from Pediatric to Adult Rheumatology
Background/Purpose: Pediatric rheumatologists have successfully improved the life expectancy and quality of life of children with systemic lupus (cSLE). cSLE has higher morbidity and mortality…
ACR Meeting Abstracts